BEDFORD, Ohio, Aug. 13 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced FDA approval to begin shipping Pentostatin for Injection. This product is AP rated and is equivalent to Nipent(R) by Hospira Inc. Pentostatin is indicated for the treatment of hairy cell leukemia.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )
“In our continuing effort to offer the most comprehensive and cost effective line of oncology and oncology adjunct products in the multisource industry, Bedford Laboratories is once again very pleased to offer this very important product,” said David Gaugh, Vice President of Bedford Laboratories.
Bedford Laboratories will supply latex-free Pentostatin for Injection as a sterile lyophilized powder in a single-dose vial containing 10mg of pentostatin. Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169, or from the company’s web site, www.bedfordlabs.com.
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business, segment Prescription Medicines, on research and development.
For more information on the Boehringer Ingelheim Corporation, please visit http://us.boehringer-ingelheim.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comBedford Laboratories
CONTACT: Jason Kurtz of Bedford Laboratories, 1-800-562-4797, ext 3668
